Literature DB >> 8035925

The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part VI. Family history assessment: a multicenter study of first-degree relatives of Alzheimer's disease probands and nondemented spouse controls.

J M Silverman1, K Raiford, S Edland, G Fillenbaum, J C Morris, C M Clark, W Kukull, A Heyman.   

Abstract

Although familial factors in Alzheimer's disease (AD) are well established, uniform family-history assessment in genetic and epidemiologic studies of AD is needed to reconcile the divergent estimates of the cumulative risk of this illness among relatives of AD probands. To answer the need, the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) has developed a standardized Family History Assessment of AD to identify the presence of AD, Parkinson's disease (PD), and Down's syndrome (DS) in family members. This paper describes the use of this new assessment instrument in 118 patients with AD (estimated mean age at onset [+/- SD] = 64.5 +/- 7.7 years) and their nondemented spouses who were enrolled in 11 different CERAD sites in the U.S. The first-degree relatives of the probands with AD had a significantly greater cumulative risk (p < 0.005) of AD or primary progressive dementia (24.8%) than did the relatives of spouse controls (15.2%). Furthermore, the cumulative risk for this disorder among female relatives of probands was significantly greater than that among male relatives. There were no differences between the families of probands and controls for the numbers of affected first-degree relatives with PD or DS. This is the first reported multicenter family-history study of AD, and it supports earlier reports of familial factors in AD and indicates a higher risk to female relatives of AD probands. The CERAD Family History Assessment instrument may be useful for further multicenter and epidemiologic studies designed to delineate familial factors associated with AD.

Entities:  

Mesh:

Year:  1994        PMID: 8035925     DOI: 10.1212/wnl.44.7.1253

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  18 in total

Review 1.  Role of mitochondrial homeostasis and dynamics in Alzheimer's disease.

Authors:  J Eva Selfridge; Lezi E; Jianghua Lu; Russell H Swerdlow
Journal:  Neurobiol Dis       Date:  2012-01-10       Impact factor: 5.996

Review 2.  New approaches to genetic counseling and testing for Alzheimer's disease and frontotemporal degeneration.

Authors:  Jill S Goldman
Journal:  Curr Neurol Neurosci Rep       Date:  2012-10       Impact factor: 5.081

Review 3.  Genetics, transcriptomics, and proteomics of Alzheimer's disease.

Authors:  Andreas Papassotiropoulos; Michael Fountoulakis; Travis Dunckley; Dietrich A Stephan; Eric M Reiman
Journal:  J Clin Psychiatry       Date:  2006-04       Impact factor: 4.384

4.  Clinical rationale of genetic testing in dementia.

Authors:  G B Frisoni; M Trabucchi
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-03       Impact factor: 10.154

5.  HDDD2 is a familial frontotemporal lobar degeneration with ubiquitin-positive, tau-negative inclusions caused by a missense mutation in the signal peptide of progranulin.

Authors:  Odity Mukherjee; Pau Pastor; Nigel J Cairns; Sumi Chakraverty; John S K Kauwe; Shantia Shears; Maria I Behrens; John Budde; Anthony L Hinrichs; Joanne Norton; Denise Levitch; Lisa Taylor-Reinwald; Michael Gitcho; P-H Tu; Lea Tenenholz Grinberg; Rajka M Liscic; Javier Armendariz; John C Morris; Alison M Goate
Journal:  Ann Neurol       Date:  2006-09       Impact factor: 10.422

Review 6.  The clinical problem of symptomatic Alzheimer disease and mild cognitive impairment.

Authors:  Rawan Tarawneh; David M Holtzman
Journal:  Cold Spring Harb Perspect Med       Date:  2012-05       Impact factor: 6.915

7.  Mutations in mitochondrial cytochrome c oxidase genes segregate with late-onset Alzheimer disease.

Authors:  R E Davis; S Miller; C Herrnstadt; S S Ghosh; E Fahy; L A Shinobu; D Galasko; L J Thal; M F Beal; N Howell; W D Parker
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-29       Impact factor: 11.205

8.  Gender difference in apolipoprotein E-associated risk for familial Alzheimer disease: a possible clue to the higher incidence of Alzheimer disease in women.

Authors:  H Payami; S Zareparsi; K R Montee; G J Sexton; J A Kaye; T D Bird; C E Yu; E M Wijsman; L L Heston; M Litt; G D Schellenberg
Journal:  Am J Hum Genet       Date:  1996-04       Impact factor: 11.025

9.  Consortium to Establish a Registry for Alzheimer's Disease (CERAD): the first twenty years.

Authors:  Gerda G Fillenbaum; Gerald van Belle; John C Morris; Richard C Mohs; Suzanne S Mirra; Patricia C Davis; Pierre N Tariot; Jeremy M Silverman; Christopher M Clark; Kathleen A Welsh-Bohmer; Albert Heyman
Journal:  Alzheimers Dement       Date:  2008-03       Impact factor: 21.566

10.  Molecular characterization of novel progranulin (GRN) mutations in frontotemporal dementia.

Authors:  Odity Mukherjee; Jun Wang; Michael Gitcho; Sumi Chakraverty; Lisa Taylor-Reinwald; Shantia Shears; John S K Kauwe; Joanne Norton; Denise Levitch; Eileen H Bigio; Kimmo J Hatanpaa; Charles L White; John C Morris; Nigel J Cairns; Alison Goate
Journal:  Hum Mutat       Date:  2008-04       Impact factor: 4.878

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.